Galectin Therapeutics Inc (GALT) saw an uptrend of 0.46% in the recent trading with $2.18 being its most recent. The current price level -44.15% lower than the highest price of $3.90 marked by the stock while trading over the past 52-weeks, whereas it is 200.26% higher than the lowest price of $0.73 the company dropped to over past 52-weeks. The latest news story on GALT appeared in (PR Newswire) under the title “Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going” on Jun-18-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Galectin Therapeutics Inc Earnings – What Happened With GALT
Coming around sales and income figures on GALT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Galectin Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 63.29 million. GALT does have institutional investors; and they hold 15.75% of the stock.
As on 2024-06-30, VANGUARD GROUP INC was the top most holder in Galectin Therapeutics Inc (NASDAQ:GALT) with an ownership of 2.12 million shares of the company or 3.4002 of the stake worth $4.78 million. The filing also reveals BLACKROCK INC. as the second largest holder in the company with a control over 2.5128 of the outstanding shares. Its stake is worth $3.53 million for having 1.56 million shares in hand.
ADVISOR GROUP HOLDINGS, INC. also came holding a key position in the company during the recent quarter and it now holds 1.8093 of the outstanding shares. With this there are now 120.0 institutions which have possession in GALT’s shares.
Key Metrics forGALT
Technical Analysis of Galectin Therapeutics Inc (NASDAQ:GALT) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Galectin Therapeutics Inc (GALT), we notice that the stock’s 20-day average volume is at 1,438,605 shares and 100% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 669,238 shares. And to end, GALT’s 100-day average volume is 463,089 shares with 50% of the long-term indicators pointing towards Buy for the stock.
